Novartis, Amgen Inc and the non-profit organisation Banner Alzheimer’s Institute have stopped two pivotal studies of umibecestat, a candidate Alzheimer’s drug, because a review identified a worsening in some measures of cognitive function among patients. The trial was intended to run until 2025.
